163 In the index

Mod GRF 1-29 ModGRF

A stabilized version of a natural hormone-releasing signal, used in research-peptide circles to trigger short bursts of growth hormone. Small studies confirm it does raise growth hormone briefly, but it hasn't gone through the full testing needed for approval.

Also known as CJC-1295 no DAC, SERMORELIN, Sermorelina, Sermoreline, Sermorelinum, 89243S03TE, CHEBI:9118, Groliberin, hGHRH(1-29)NH2

Effects Build muscle

Routes Subcutaneous

Legal status Research chemical

WADA Banned at all times

Molecular Structure of C₁₄₉H₂₄₆N₄₄O₄₂S

Drag to rotate · scroll to zoom

PubChem has no 3D conformer for this molecule, so this is the flat structure.

Chemistry

Formula: C149H246N44O42S
Molar mass: 3357.9
CAS: 86168-78-7
PubChem CID: 16132413
IUPAC name: (3S)-4-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-4-oxobutanoic acid
InChIKey: WGWPRVFKDLAUQJ-MITYVQBRSA-N

Reported dosing

User-reported

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 100-300 mcg per dose

Reported range 100-300 mcg per dose

Route Subcutaneous injection

Frequency 1-3 times daily

Duration 8-12 week course (unregulated use)

A modified, more stable fragment of GHRH, essentially the same active compound as CJC-1295 without DAC; not FDA-approved, sold only as a research chemical.

Where this comes from User-reported/research-chemical vendor literature; limited early pharmacology data

There is no approved human dosing for this compound. The figures above are what users and vendors report, not what has been established as safe or effective. Treat them as a record of what is done, not as guidance.